Humanin Dosage: How Much to Take, When & How

Humanin Dosage: How Much to Take, When & How

Overview

Humanin is a 21-amino acid mitochondrial-derived peptide (MDP) available in two primary routes of administration: injection and intranasal delivery. The peptide is studied for cytoprotective, anti-apoptotic, and metabolic effects, with research spanning neuroprotection, cardiovascular health, insulin sensitivity, and longevity support. Because humanin is not FDA-approved and available only as a research peptide, dosing protocols are derived from research literature and user reports rather than pharmaceutical guidelines. This guide provides practical dosing information based on available evidence and established usage patterns.

Cost: $60–$200 per month, depending on dose frequency and vendor pricing.

Standard Dosing Protocol

Injection (Subcutaneous or Intramuscular)

Standard dose range: 100–500 mcg per injection
Frequency: Once daily or 3 times per week
Common starting protocol: 100–200 mcg, 3 times per week (e.g., Monday, Wednesday, Friday)

The most commonly reported injection protocol uses 150–300 mcg, 3 times weekly. This frequency allows for consistent blood levels while minimizing potential adaptation and injection site irritation. Once-daily dosing (100–200 mcg) is also used, particularly by individuals seeking higher compliance or daily ritualization.

Administration depth: Subcutaneous injection (under the skin, typically at the abdomen, thigh, or arm) is the standard route. Inject slowly to reduce localized irritation.

Intranasal (Nasal Spray or Powder)

Standard dose range: 200–400 mcg per administration
Frequency: Once daily
Common protocol: 300 mcg, once daily in the morning

Intranasal humanin avoids injection site irritation and offers convenience. Doses are typically higher than injection equivalents (200–400 mcg) due to lower bioavailability through mucosal absorption. Once-daily morning administration is standard to maintain consistent daily exposure.

Dosing by Goal

For Metabolic Support & Fat Loss

Recommended dose: 200–300 mcg via injection, 3 times per week
Or: 300 mcg intranasal, once daily

Animal research shows humanin reduces visceral fat and improves insulin sensitivity. Users pursuing metabolic benefits typically employ mid-range doses with consistent frequency to support steady metabolic signaling. Pair with resistance training and dietary adherence for optimal results, as humanin alone shows limited fat loss without lifestyle modification in human contexts.

Duration: 8–12 weeks minimum to assess metabolic changes; longer-term studies in humans are unavailable.

For Neuroprotection & Cognitive Support

Recommended dose: 150–300 mcg via injection, 3 times per week
Or: 300–400 mcg intranasal, once daily

Cognitive benefits are primarily supported by animal and mechanistic research. Early human observational studies suggest associations between higher humanin levels and preserved cognition during aging. Dosing for cognition mirrors general neuroprotective protocols; lower-to-mid-range doses are preferred to minimize any risk of transient hypoglycemia, which could temporarily impair cognitive function.

Duration: 12+ weeks; longer trials necessary to assess cognitive outcomes in humans.

For Cardiovascular Health

Recommended dose: 200–300 mcg via injection, 3 times per week
Or: 300 mcg intranasal, once daily

Observational evidence shows lower circulating humanin associates with myocardial infarction and coronary artery disease risk. Mid-range dosing protocols are used to support cardiovascular markers, though no human trials have proven supplemental humanin directly prevents cardiac events. Consistent dosing frequency is prioritized over higher peak doses.

Duration: 12+ weeks for cardiovascular marker assessment.

For Muscle & Mitochondrial Function

Recommended dose: 250–400 mcg via injection, 3 times per week
Or: 300–400 mcg intranasal, once daily

Animal studies indicate humanin improves skeletal muscle autophagy and mitochondrial function. Users pursuing muscle or athletic benefits often employ higher mid-to-upper-range doses, particularly when combined with resistance training. Some advanced users combine injection (3x weekly) with daily intranasal dosing, though human data on combination protocols is absent.

Duration: 8–16 weeks paired with progressive resistance training.

For Recovery & Anti-Inflammation

Recommended dose: 200–300 mcg via injection, 3–5 times per week
Or: 300 mcg intranasal, once daily

Anti-inflammatory mechanistic evidence is strong in animal models. Users managing injury recovery or chronic inflammation often use more frequent injection protocols (4–5 times weekly at 150–250 mcg) to maintain elevated circulating levels. Combination with exercise and antioxidant support (as shown in one human RCT with astaxanthin) may enhance effects.

Duration: 4–12 weeks, depending on injury severity and recovery timeline.

How to Administer

Injection Administration

Equipment needed:

• Insulin syringe (31G or smaller needle preferred)
• Alcohol prep pad
• Sterile vial of humanin powder or solution
• Sterile saline for reconstitution (if using powder)

Step-by-step:

1. Reconstitute powder with sterile saline according to vendor instructions (typical reconstitution yields 1–2 mg/mL concentration).
2. Draw the calculated dose into the syringe (e.g., 200 mcg = 0.1–0.2 mL, depending on concentration).
3. Cleanse injection site with alcohol pad; allow 30 seconds to dry.
4. Pinch skin slightly; insert needle at 45–90-degree angle into subcutaneous tissue.
5. Inject slowly over 3–5 seconds to reduce localized irritation.
6. Withdraw needle; apply light pressure with sterile gauze if bleeding occurs.
7. Rotate injection sites daily to minimize irritation (abdomen, thighs, upper arms).

Storage: Reconstituted humanin should be stored at 2–8°C (refrigerated) and used within 2–4 weeks, depending on vendor stability data. Protect from light.

Intranasal Administration

Equipment needed:

• Nasal spray bottle or powder insufflator (vendor-dependent)
• Tissues

Step-by-step:

1. Clear nasal passages gently or use saline rinse if congested.
2. Tilt head slightly back or use upright posture, depending on device design.

3. Insert nozzle into one nostril; depress or activate to deliver dose.
4. Repeat in opposite nostril if dual-nostril dosing is specified.
5. Remain upright for 30 seconds to allow mucosal absorption.
6. Avoid blowing nose immediately after administration.

Storage: Store intranasal formulation at room temperature unless otherwise instructed by vendor. Most nasal sprays remain stable for 3–6 months.

Cycling & Timing

Standard Cycling Protocol (Injection)

8-week on / 4-week off cycle:

• Weeks 1–8: 150–300 mcg, 3 times per week
• Weeks 9–12: Complete break
• Repeat cycle

This pattern allows for assessment of sustained vs. cycled dosing effects and may reduce potential tolerance or receptor desensitization. Many users report subjective benefits persist partially into off-weeks, suggesting some biological carryover.

Continuous Dosing Protocol (Intranasal or Injection)

Ongoing: 200–300 mcg daily or 3x weekly without planned breaks

Some users employ continuous low-dose protocols year-round, particularly for chronic conditions (e.g., metabolic support, neuroprotection). No human data suggests optimal break intervals, so cycling is optional and based on individual preference and monitoring.

Timing Considerations

Injection timing: No specific time-of-day advantage has been demonstrated. Three-times-weekly dosing is typically spread evenly (e.g., Monday, Wednesday, Friday) to maintain stable circulating levels.

Intranasal timing: Once-daily dosing is commonly scheduled in the morning with food to minimize any acute hypoglycemia risk, particularly in insulin-sensitive individuals. Some users dose in the evening if monitoring for sleep effects.

Beginner vs. Advanced Dosing

Beginner Protocol (First 4–8 Weeks)

Injection: 100–150 mcg, 3 times per week
Or: Intranasal: 200 mcg, once daily

Start at the lower end of dosing ranges to assess tolerance and individual response. Many first-time users report mild transient fatigue or headache at initiation; lower starting doses minimize these temporary effects. Assess for injection site reactions or nasal mucosal irritation before escalating dose.

Intermediate Protocol (Weeks 8–16)

Injection: 200–250 mcg, 3 times per week
Or: Intranasal: 300 mcg, once daily

After establishing tolerance, escalate to mid-range doses to align with research protocols and user-reported efficacy ranges. At this level, most users report stable tolerability and measurable subjective or objective benefits (e.g., improved energy, reduced inflammation markers).

Advanced Protocol (16+ Weeks)

Injection: 300–500 mcg, 3 times per week
Or: Combination: 250 mcg injection, 3x weekly + 300 mcg intranasal, daily

Advanced users may employ higher doses or combination protocols, though human safety data at these doses is limited. Combination protocols are entirely user-derived; no clinical trials compare injection + intranasal combination dosing. Reserve higher doses for experienced users who have tolerated mid-range doses without adverse effects.

Common Dosing Mistakes

1. Inconsistent frequency
Dosing once per week or every 10 days creates unstable circulating levels and may reduce efficacy. Maintain consistent 3-times-weekly or daily schedules.

2. Premature dose escalation
Increasing from beginner to advanced doses within 2–3 weeks elevates risk of transient hypoglycemia, fatigue, or headache. Allow 4–8 weeks at each dose level before escalating.

3. Overdosing on intranasal delivery
Some users assume intranasal doses should match injection doses (100–300 mcg), resulting in suboptimal absorption. Intranasal effective doses are 200–400 mcg due to lower mucosal bioavailability.

4. Inadequate storage and reconstitution
Reconstituted humanin powder left at room temperature or in direct light degrades rapidly. Always refrigerate and use within 2–4 weeks.

5. Ignoring hypoglycemia risk
Humanin improves insulin sensitivity, which may transiently lower blood glucose in insulin-sensitive individuals (particularly those with type 2 diabetes on medications). Monitor fasting glucose and pair humanin with adequate carbohydrate intake, especially during initial weeks.

6. Combining with other insulin-sensitizing supplements without monitoring
Stacking humanin with other insulin-sensitizers (e.g., berberine, metformin, inositol) without blood glucose monitoring risks symptomatic hypoglycemia. Start humanin alone or with medical oversight if combining.

7. No assessment period
Using humanin without a defined endpoint to assess benefits (e.g., 12 weeks) makes it impossible to determine if effects justify cost ($60–$200/month). Define measurable outcomes before starting.

Dosage Summary Table

Important Disclaimer

This guide is educational content intended to provide practical information about humanin dosing protocols. It is not medical advice, and should not replace consultation with a qualified healthcare provider. Humanin is not FDA-approved and is available only as a research peptide; its quality, purity, and dosing accuracy depend entirely on vendor reliability and are not regulated by pharmaceutical authorities.

Before using humanin, consult with a physician, particularly if you:

• Have a history of diabetes or blood glucose dysregulation
• Take insulin or glucose-lowering medications
• Have cardiovascular disease or are on blood-pressure medications
• Are pregnant, breastfeeding, or planning pregnancy
• Have liver or kidney disease
• Are taking other supplements or medications that affect glucose or inflammation

Adverse effects including transient hypoglycemia, injection site irritation, fatigue, and headache are possible. Long-term safety data in humans is limited. Monitor response carefully, and discontinue use and seek medical attention if serious adverse effects occur.